The FDA's approval of Vykat XR offers hope for individuals with Prader-Willi syndrome (PWS), a rare disorder causing insatiable hunger. This extended-release drug targets hyperphagia, significantly improving quality of life for patients like 16-year-old Dean Shenk, whose symptoms dramatically lessened during clinical trials. While expensive, Vykat XR calms overactive hunger neurons, offering a potential breakthrough in understanding and treating obesity. However, concerns remain regarding reduced federal funding for obesity research, potentially hindering future progress.

Prepared by Olivia Bennett and reviewed by editorial team.